EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Rivaroxaban for Venous Thromboembolism (VTE) in Paediatric Patients: an institutional retrospective observational study from the Low/Middle Income setting in Pakistan

Aimen Mahmood, Bushra Moiz, Zehra Fadoo, Asim Belgaumi, Naureen Mushtaq, Sadaf Altaf

Journal of the Pakistan Medical Association · 2025

DOI: 10.47391/jpma.11091 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the Pakistan Medical Association, 2025. Verfasst von Aimen Mahmood und 5 weiteren Autor:innen. Beteiligte Einrichtung: 5th Year MBBS Student, Aga Khan University, Karachi, Pakistan. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thromboembolism, Factor Xa Inhibitors, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate bleeding events, mortality, recurrence and prescribing practices in paediatric and adolescent patients of venous thromboembolism using direct acting oral anticoagulants (DOACs).

Method

The descriptive, retrospective study was conducted from November 2021 to May 2022 at the Aga Khan University Hospital and comprised data from 2017 to 2021 of patients from birth to 18 years who received DOACs for prophylaxis or treatment purposes of venous thromboembolism. Data was analysed using STATA MP.15.

Results

Of the 45 patients, 37(82.2%) were males and 8(17.8%) were females. The overall median age was 16 years (interquartile range: 12.5-18 years). Of the total, 33(73.3%) patients were treated for acute venous thromboembolism, while 12(26.7%) received anticoagulants as prophylaxis. Complete thrombus resolution was achieved in 15(45.5%) patients, partial resolution in 3 (9.1%), and no resolution in 4(12.1%). Recurrence of venous thromboembolism occurred in 2(6%) patients. Enoxaparin was prescribed in 24(53.3%) cases, rivaroxaban in 14(31.1%) and heparin in 7(15.6%). There were 13(28.9%) deaths in the cohort.

Conclusion

Rivaroxaban may be safe in the management of paediatric venous thromboembolism, with no major bleeding complications observed in our study. Key Words: Rivaroxaban, Direct oral anticoagulants, Paediatric, Low middle-income country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanVenous ThromboembolismFactor Xa InhibitorsAnticoagulantsHumansChildMaleFemaleRetrospective StudiesAdolescentPakistanChild, PreschoolInfantEnoxaparinHemorrhageRecurrenceHeparinInfant, Newborn

Stichwörter der Autor:innen

Rivaroxaban, Direct oral anticoagulants, Paediatric, Low middle-income country.

Substanzen

RivaroxabanFactor Xa InhibitorsAnticoagulantsEnoxaparinHeparin

Autor:innen und Institutionen

  • 5th Year MBBS Student, Aga Khan University, Karachi, Pakistan.
  • Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
  • Department of Oncology, Aga Khan University, Karachi, Pakistan.

Zitieren

APA

Mahmood, A., Moiz, B., Fadoo, Z., Belgaumi, A., Mushtaq, N., & Altaf, S. (2025). Rivaroxaban for Venous Thromboembolism (VTE) in Paediatric Patients: an institutional retrospective observational study from the Low/Middle Income setting in Pakistan. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.11091

Vancouver

Mahmood A, Moiz B, Fadoo Z, Belgaumi A, Mushtaq N, Altaf S. Rivaroxaban for Venous Thromboembolism (VTE) in Paediatric Patients: an institutional retrospective observational study from the Low/Middle Income setting in Pakistan. Journal of the Pakistan Medical Association. 2025. doi:10.47391/jpma.11091

BibTeX
@article{Mahmood2025,
  author = {Mahmood, Aimen and Moiz, Bushra and Fadoo, Zehra and Belgaumi, Asim and Mushtaq, Naureen and Altaf, Sadaf},
  title = {Rivaroxaban for Venous Thromboembolism (VTE) in Paediatric Patients: an institutional retrospective observational study from the Low/Middle Income setting in Pakistan},
  journal = {Journal of the Pakistan Medical Association},
  year = {2025},
  doi = {10.47391/jpma.11091}
}
Kostenlos starten →